2-(BOC- 氨基)-5-甲基吡啶 | 562074-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(BOC- 氨基)-5-甲基吡啶
• 中文别名: 2-(BOC-氨基)-5-甲基吡啶
• 英文名称: tert-butyl (5-methylpyridin-2-yl)carbamate
• 英文别名: Tert-butyl 5-methylpyridin-2-ylcarbamate；tert-butyl N-(5-methylpyridin-2-yl)carbamate
• CAS: 562074-43-5
• 化学式: C₁₁H₁₆N₂O₂
• mdl: MFCD07776934
• 分子量: 208.26
• InChiKey: QSGRLGXFSNTKDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(BOC-Amnio)-5-methylpyridine
Synonyms: tert-Butyl N-(5-methylpyridin-2-yl)carbamate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(BOC-Amnio)-5-methylpyridine
CAS number: 562074-43-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H16N2O2
Molecular weight: 208.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(BOC- 氨基)-5-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 2.5h， 生成 (5-溴甲基-吡啶-2-基)-氨基甲酸叔丁酯
  参考文献：
  名称：

  [DE] IMIDAZOL-DERIVATE ALS TAFIA-INHIBITOREN
  [EN] IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS
  [FR] DERIVES D'IMIDAZOLE SERVANT D'INHIBITEURS DE TAFIA

  摘要：

  这项发明涉及公式（I）的连接物，其为激活的凝血酶激活纤溶抑制剂。公式I的连接物适用于制备用于预防和治疗与血栓形成、栓塞、高凝状态或纤维化变化相关的疾病的药物。

  公开号：

  WO2005105781A1
• 作为产物：
  描述：

  2-溴-5-甲基吡啶 、 氨基甲酸叔丁酯 在 氯化镍二甲氧基乙烷 、 (4,4'-二叔丁基-2,2'-联吡啶)双[(2-吡啶基)苯基]铱(III)六氟磷酸盐 、 4,4'-二叔丁基-2,2'-二吡啶 、 四甲基胍 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以74%的产率得到2-(BOC- 氨基)-5-甲基吡啶
  参考文献：
  名称：

  通过光敏镍催化的氨基甲酸酯的N-酰化反应

  摘要：

  报道了在室温下可见光介导的Cbz-胺/ Boc-胺与芳基亲电试剂介导的Ni（II）催化的光氧化还原N-芳基化的高效方法。该方法提供了广泛使用的N-芳族和N-杂芳族氨基甲酸酯产品的通用途径，这些产品可用于合成几种生物活性分子，并且相对于传统的钯催化的布赫瓦尔德反应具有明显的优势。

  DOI：

  10.1021/acs.joc.8b02182

文献信息

• [EN] TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] ALCYNES TRICYCLIQUES QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2014035872A1

  公开（公告）日：2014-03-06

  The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的式I的三环炔化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Synthesis of 3-Aminoimidazo[1,2-<i>a</i>]pyridines from α-Aminopyridinyl Amides
  作者：Sophie Régnier、William S. Bechara、André B. Charette

  DOI：10.1021/acs.joc.6b01324

  日期：2016.11.4

  3-Aminoimidazo[1,2-a]pyridines are rapidly synthesized via a facile and mild cyclodehydration-aromatization reaction starting from readily available amides. The cyclodehydration step is mediated by the activation of N-Boc-protected 2-aminopyridine-containing amides by triflic anhydride (Tf2O) in the presence of 2-methoxypyridine (2-MeO-Py). Subsequently, the addition of K2CO3 in THF ensured a clean

  3-氨基咪唑并[1,2- a ]吡啶是通过容易和温和的环脱水-芳构化反应迅速合成的，从容易获得的酰胺开始。在2-甲氧基吡啶（2-MeO-Py）存在下，通过三氟甲磺酸酐（Tf 2 O）活化N -Boc保护的含2-氨基吡啶的酰胺来介导环脱水步骤。随后，添加K 2 CO 3在THF中的溶剂确保干净的脱保护-芳构化序列，以提供所需的杂环。在优化的程序下，可以容忍各种各样的官能团和取代模式，并且对于稠合的双环3-氮杂-杂环化合物，获得了良好或优异的收率。另外，发现该反应可扩展至克级，并且可以用未保护的无环酰胺前体进行。我们还发现，所得产物是Pd和Ru催化的CH芳基化反应的有价值的中间体，从而可以精制各种功能化的结构单元。
• [DE] IMIDAZOL-DERIVATE ALS TAFIA-INHIBITOREN<br/>[EN] IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS<br/>[FR] DERIVES D'IMIDAZOLE SERVANT D'INHIBITEURS DE TAFIA
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005105781A1

  公开（公告）日：2005-11-10

  Die Erfindung betrifft Verbindungen der Formel (I), die Inhibitoren von aktivierter Thrombin-aktivierbarer Fibrinolyse Inhibitor sind. Die Verbindungen der Formel I eignen sich zur Herstellung von Arzneimitteln zur Prophylaxe und Therapie von Erkrankungen, die mit Thrombosen, Embodien, Hyperkoagulabilität oder fibrotischen Veränderungen einhergehen.

  这项发明涉及公式（I）的连接物，其为激活的凝血酶激活纤溶抑制剂。公式I的连接物适用于制备用于预防和治疗与血栓形成、栓塞、高凝状态或纤维化变化相关的疾病的药物。
• [EN] DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINES ET DE QUINOXALINES EN TANT QU'INHIBITEURS DE PROTÉINE TYROSINE KINASES
  申请人：NOVARTIS AG

  公开号：WO2009141386A1

  公开（公告）日：2009-11-26

  The invention relates to compounds of Formula (I), wherein the substituens are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  该发明涉及式（I）的化合物，其中取代基如规范中定义的那样，以自由形式或作为药用盐、溶剂合物、酯、其N-氧化物的形式存在；其制备方法；含有这种化合物的药物，特别是用于治疗一个或多个蛋白酪氨酸激酶介导的疾病。
• Process for the preparation of an enantiomerically enriched thio compound
  申请人：DSM N.V.

  公开号：EP1325908A1

  公开（公告）日：2003-07-09

  The invention relates to a process for the preparation of an enantiomerically enriched compound of formula 1 or a salt thereof, in which R1 and R2 each independently represent an (hetero)alkyl or (hetero)aryl group, wherein R1-C(O)-SH or a salt thereof, with R1 as defined above, is reacted with R2-C(C=CH2)-C(O)OH with R2 as defined above, wherein the reaction takes place in the presence of catalyst is an enantiomerically enriched Lewis acid containing a transition metal chosen from the group of Ti, Zr and Hf or a combination thereof and at least one enantiomerically enriched ligand, and in the presence of an alkali metal ion, an alkaline earth metal ion or an ammonium ion.

  该发明涉及一种制备式1的对映富集化合物或其盐的过程，其中R1和R2各自独立表示(hetero)alkyl或(hetero)aryl基团，其中R1-C(O)-SH或其盐，其中R1如上定义，与R2-C(C=CH2)-C(O)OH反应，其中R2如上定义，反应在存在催化剂的情况下进行，所述催化剂是对映富集的含有过渡金属的Lewis酸，所述过渡金属选择自Ti、Zr和Hf组合以及至少一种对映富集的配体，以及存在碱金属离子、碱土金属离子或铵离子。